financetom
Business
financetom
/
Business
/
Nukkleus Stock Is Ripping Higher Today: What's Happening?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nukkleus Stock Is Ripping Higher Today: What's Happening?
Aug 26, 2025 10:32 AM

Nukkleus Inc ( NUKK ) shares are soaring Tuesday after the company launched a defense subsidiary and secured an exclusive distribution agreement with BladeRanger.

Key Details: Nukkleus ( NUKK ) announced that it established Nukkleus Defense Technologies Inc as a wholly owned subsidiary for defense-focused activities. The move aligns with the company’s strategy of acquiring and developing high-growth businesses within the aerospace and defense industry.

In connection with the announcement, Nukkleus ( NUKK ) entered into an exclusive three-year U.S. distribution agreement with BladeRanger to bring the company’s proprietary drone payload technology to the U.S. market. The deal includes an option to extend the agreement for an additional five years.

“Our expansion into defense reflects both the evolving global security landscape and the opportunities we see in advanced drone technologies,” said Menny Shalom, CEO of Nukkleus ( NUKK ).

“By establishing Nukkleus Defense Technologies and securing this exclusive partnership with BladeRanger, we are positioning ourselves to deliver transformative solutions to U.S. defense and homeland security customers while driving long-term value for our shareholders.”

Nukkleus ( NUKK ) will provide an upfront licensing payment and has committed to minimum annual purchase volumes that will increase progressively over the three-year term.

NUKK Analysis: The price action in Nukkleus ( NUKK ) stock indicates a bullish trend, with higher highs and higher lows being established. Volume is robust at 1.8 million shares, significantly above the average volume of approximately 362,000, suggesting strong buying interest. This volume spike confirms the recent price increase and supports the upward movement.

The RSI is calculated at 70.12, indicating the stock is approaching overbought territory, which could lead to a pullback if buying pressure wanes. The MACD shows a bullish crossover, but the lines are converging, suggesting a potential slowdown in momentum.

Chart patterns reveal a possible ascending triangle formation, with the upper trend line at $5.21 and the lower trend line forming around $4.80. This pattern often precedes a breakout, reinforcing the bullish outlook if the stock can maintain momentum above resistance.

NUKK Price Action: Nukkleus ( NUKK ) shares were up 21% at $6.04 at the time of publication on Tuesday. The stock has already been halted multiple times for volatility in Tuesday’s session, according to Benzinga Pro.

Read Next:

Semtech Posts Upbeat Earnings, Joins Nio, Heico, Bank of Nova Scotia And Other Big Stocks Moving Higher On Tuesday

This illustration was generated using artificial intelligence via Midjourney.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved